These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 26442301)

  • 1. [Early diagnosis of prostate cancer by combined use of Trp-p8 expression and PSA density of the transition zone].
    Zhang XS; Zhang Y; Wu PX; Liu SJ; Zhou JY; Liu SX
    Zhonghua Nan Ke Xue; 2015 Aug; 21(8):724-8. PubMed ID: 26442301
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Assessment of serum level of prostate-specific antigen adjusted for the transition zone volume in early detection of prostate cancer.
    Ferreira MD; Koff WJ
    Int Braz J Urol; 2005; 31(2):137-45; discussion 146. PubMed ID: 15877833
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Multiple tumor marker analyses (PSA, hK2, PSCA, trp-p8) in primary prostate cancers using quantitative RT-PCR.
    Fuessel S; Sickert D; Meye A; Klenk U; Schmidt U; Schmitz M; Rost AK; Weigle B; Kiessling A; Wirth MP
    Int J Oncol; 2003 Jul; 23(1):221-8. PubMed ID: 12792797
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Urinary microRNA-based signature improves accuracy of detection of clinically relevant prostate cancer within the prostate-specific antigen grey zone.
    Salido-Guadarrama AI; Morales-Montor JG; Rangel-Escareño C; Langley E; Peralta-Zaragoza O; Cruz Colin JL; Rodriguez-Dorantes M
    Mol Med Rep; 2016 Jun; 13(6):4549-60. PubMed ID: 27081843
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison between PSA density, free PSA percentage and PSA density in the transition zone in the detection of prostate cancer in patients with serum PSA between 4 and 10 ng/mL.
    Gregorio EP; Grando JP; Saqueti EE; Almeida SH; Moreira HA; Rodrigues MA
    Int Braz J Urol; 2007; 33(2):151-60. PubMed ID: 17488533
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A precursor form of prostate-specific antigen is more highly elevated in prostate cancer compared with benign transition zone prostate tissue.
    Mikolajczyk SD; Millar LS; Wang TJ; Rittenhouse HG; Marks LS; Song W; Wheeler TM; Slawin KM
    Cancer Res; 2000 Feb; 60(3):756-9. PubMed ID: 10676664
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Differential diagnosis of prostate cancer and benign prostate hyperplasia using two-dimensional electrophoresis.
    Charrier JP; Tournel C; Michel S; Comby S; Jolivet-Reynaud C; Passagot J; Dalbon P; Chautard D; Jolivet M
    Electrophoresis; 2001 May; 22(9):1861-6. PubMed ID: 11425243
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of Vitronectin Expression in Prostate Cancer and the Clinical Significance of the Association of Vitronectin Expression with Prostate Specific Antigen in Detecting Prostate Cancer.
    Niu Y; Zhang L; Bi X; Yuan S; Chen P
    Urol J; 2016 Mar; 13(1):2527-32. PubMed ID: 26945657
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prostate specific antigen density for discriminating prostate cancer from benign prostatic hyperplasia in the gray zone of prostate-specific antigen.
    Uno H; Koide T; Kuriyama M; Ban Y; Deguchi T; Kawada Y
    Hinyokika Kiyo; 1999 Jul; 45(7):457-61. PubMed ID: 10466060
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Free/total prostate specific antigen ratio (%PSA) to predict probability of prostate cancer].
    Zenimoto M; Kita M; Arai T; Murayama T; Mori M
    Rinsho Byori; 2003 Oct; 51(10):969-73. PubMed ID: 14653195
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prostate Specific Antigen, Mean Platelet Volume, and Platelet Distribution Width in Combination to Discriminate Prostate Cancer from Benign Prostate Hyperplasia.
    Fu S; Zhang X; Niu Y; Wang RT
    Asian Pac J Cancer Prev; 2018 Mar; 19(3):699-702. PubMed ID: 29580043
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ki-67 and PCNA expression in prostate cancer and benign prostatic hyperplasia.
    Zhong W; Peng J; He H; Wu D; Han Z; Bi X; Dai Q
    Clin Invest Med; 2008; 31(1):E8-E15. PubMed ID: 18312749
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Screening, identification of prostate cancer urinary biomarkers and verification of important spots.
    Zhao H; Zhao X; Lei T; Zhang M
    Invest New Drugs; 2019 Oct; 37(5):935-947. PubMed ID: 30610587
    [TBL] [Abstract][Full Text] [Related]  

  • 14. miRNA-21 as High Potential Prostate Cancer Biomarker in Prostate Cancer Patients in Indonesia.
    Gunawan RR; Astuti I; Danarto HR
    Asian Pac J Cancer Prev; 2023 Mar; 24(3):1095-1099. PubMed ID: 36974566
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Significance and limitations of f/tPSA in differential diagnosis of prostate cancer with tPSA levels between 4 and 10 ng/ml].
    Chen ZD; Wei SM; Cai SL
    Zhonghua Wai Ke Za Zhi; 2004 May; 42(10):593-5. PubMed ID: 15265401
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [The role of prostate specific antigen in diagnosis of localized adenocarcinoma of the prostate. Nara Uro-Oncology Research Group].
    Hirao Y; Ozono S; Kagebayashi Y; Yoshi M; Tani Y; Uemura H; Momose H; Okajima E
    Hinyokika Kiyo; 1996 Oct; 42(10):795-804. PubMed ID: 8951478
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical utility of the interaction between lectin and serum prostate specific antigen in prostate cancer.
    Batabyal SK; Majhi R; Basu PS
    Neoplasma; 2009; 56(1):68-71. PubMed ID: 19152248
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Discrimination of men with prostate cancer from those with benign disease by measurements of human glandular kallikrein 2 (HK2) in serum.
    Becker C; Piironen T; Pettersson K; Björk T; Wojno KJ; Oesterling JE; Lilja H
    J Urol; 2000 Jan; 163(1):311-6. PubMed ID: 10604382
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prostate health index and prostate cancer gene 3 score but not percent-free Prostate Specific Antigen have a predictive role in differentiating histological prostatitis from PCa and other nonneoplastic lesions (BPH and HG-PIN) at repeat biopsy.
    De Luca S; Passera R; Fiori C; Bollito E; Cappia S; Mario Scarpa R; Sottile A; Franco Randone D; Porpiglia F
    Urol Oncol; 2015 Oct; 33(10):424.e17-23. PubMed ID: 26162485
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Comparison of PSAD and PSAD-TZ value in prostatic hyperplasia and prostatic cancer].
    Fu Q; Yao DH; Jiang YQ
    Zhonghua Nan Ke Xue; 2002 Dec; 8(6):411-3. PubMed ID: 12593013
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.